Network meta-analysis

Level 2 or 3 hypoglycemia (participants)

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)Convergence criteria not all met

Randomized trials

Treatments

37,060

Participants

6,323

Events

In plain language

Across 75 trials with 37,060 participants, 0 of 36 treatments had a clearly better result than placebo on level 2 or 3 hypoglycemia (participants), 7 a clearly worse one, and for 29 the evidence could not tell them apart from placebo. The most favorable estimate was for Vildagliptin: hazard ratio (from event counts) 0.48 (95% credible interval 0.01 to 34.67).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Vildagliptin VILDAGLIPTIN	0.48 (0.01 to 34.67)	0.01 to 38.37	Unclear
Canagliflozin CANAGLIFLOZIN	0.50 (0.11 to 1.99)	0.09 to 2.52	Unclear
Semaglutide tablet SEMA_PO	0.87 (0.28 to 2.72)	0.21 to 3.57	Unclear
Metformin METFORMIN	0.89 (0.27 to 2.63)	0.20 to 3.51	Unclear
Pioglitazone PIOGLITAZONE	0.95 (0.23 to 3.59)	0.18 to 4.79	Unclear
Liraglutide injection LIRA_SC	0.96 (0.53 to 1.69)	0.32 to 2.62	Unclear
Sitagliptin SITAGLIPTIN	1.03 (0.55 to 1.82)	0.34 to 2.85	Unclear
Dulaglutide injection DULA_SC	1.03 (0.57 to 1.75)	0.35 to 2.87	Unclear
Semaglutide injection SEMA_SC	1.12 (0.50 to 2.19)	0.34 to 3.31	Unclear
Beinaglutide injection BEIN_SC	1.12 (0.25 to 4.56)	0.20 to 5.98	Unclear
Rosiglitazone ROSIGLITAZONE	1.16 (0.29 to 4.48)	0.22 to 5.71	Unclear
Insulin glargine with lixisenatide injection IGLARLIXI_SC	1.25 (0.37 to 4.45)	0.29 to 5.82	Unclear
Liraglutide and metformin injection LIRAMETF_SC	1.35 (0.24 to 6.60)	0.19 to 8.47	Unclear
Taspoglutide injection TASP_SC	1.36 (0.70 to 2.74)	0.46 to 4.15	Unclear
Visepegenatide injection VISEPE_SC	1.39 (0.51 to 3.96)	0.37 to 5.53	Unclear
Albiglutide injection ALBI_SC	1.42 (0.64 to 3.06)	0.41 to 4.44	Unclear
Exenatide extended release injection EXENER_SC	1.43 (0.43 to 4.59)	0.32 to 6.05	Unclear
Orforglipron tablet ORFO_PO	1.52 (0.07 to 68.91)	0.06 to 75.62	Unclear
Liraglutide plus canagliflozin injection CANALIRA_SC	1.55 (0.24 to 9.52)	0.20 to 11.52	Unclear
Lixisenatide injection LIXI_SC	1.61 (1.14 to 2.34)	0.63 to 4.22	Worse
Exenatide injection EXEN_SC	1.68 (1.11 to 2.50)	0.62 to 4.34	Worse
Exenatide and rosiglitazone injection EXENROSI_SC	1.72 (0.44 to 6.43)	0.34 to 8.27	Unclear
Tirzepatide injection TIRZ_SC	1.75 (0.17 to 23.12)	0.14 to 26.47	Unclear
Empagliflozin EMPAGLIFLOZIN	2.03 (0.21 to 26.09)	0.18 to 29.86	Unclear
Premixed insulin INS_PREMIX	2.04 (0.87 to 4.99)	0.61 to 7.62	Unclear
Efpe sc EFPE_SC	2.35 (0.16 to 70.68)	0.15 to 78.11	Unclear
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	2.37 (0.57 to 9.85)	0.45 to 12.70	Unclear
Insulin glargine INS_GLARGINE	2.43 (1.41 to 4.10)	0.85 to 6.54	Worse
HRS-7535 tablet HRS7535_PO	2.43 (0.53 to 15.12)	0.43 to 18.00	Unclear
Insulin aspart (prandial) INS_ASPART	2.50 (0.40 to 16.81)	0.33 to 19.61	Unclear
Insulin dose increase OTHER_ACTIVE_insulin_dose_increase	2.70 (0.64 to 11.31)	0.50 to 14.74	Unclear
Insulin lispro (prandial) INS_LISPRO	2.73 (1.27 to 5.64)	0.86 to 8.64	Worse
Standard care or no added treatment STANDARD_CARE	3.14 (1.11 to 8.55)	0.80 to 11.40	Worse
Glimepiride GLIMEPIRIDE	3.34 (1.54 to 6.91)	1.00 to 10.11	Worse
Mazdutide injection MAZD_SC	5.02 (0.31 to 151)	0.27 to 167	Unclear
Danuglipron tablet DANU_PO	7.07 (1.00 to 101)	0.81 to 123	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	VILDAGLIPTIN	CANAGLIFLOZIN	SEMA_PO	METFORMIN	PIOGLITAZONE	LIRA_SC	SITAGLIPTIN	DULA_SC	SEMA_SC	BEIN_SC	ROSIGLITAZONE	IGLARLIXI_SC	LIRAMETF_SC	TASP_SC	VISEPE_SC	ALBI_SC	EXENER_SC	ORFO_PO	CANALIRA_SC	LIXI_SC	EXEN_SC	EXENROSI_SC	TIRZ_SC	EMPAGLIFLOZIN	INS_PREMIX	EFPE_SC	OTHER_ACTIVE_basal_bolus_insulin	INS_GLARGINE	HRS7535_PO	INS_ASPART	OTHER_ACTIVE_insulin_dose_increase	INS_LISPRO	STANDARD_CARE	GLIMEPIRIDE	MAZD_SC	DANU_PO
PLACEBO	PLACEBO	2.06 0.03 to 160	1.99 0.50 to 8.95	1.14 0.37 to 3.63	1.12 0.38 to 3.67	1.05 0.28 to 4.33	1.04 0.59 to 1.90	0.97 0.55 to 1.82	0.97 0.57 to 1.76	0.89 0.46 to 1.99	0.89 0.22 to 3.98	0.86 0.22 to 3.47	0.80 0.22 to 2.67	0.74 0.15 to 4.16	0.73 0.36 to 1.42	0.72 0.25 to 1.97	0.70 0.33 to 1.57	0.70 0.22 to 2.35	0.66 0.01 to 15.26	0.65 0.11 to 4.20	0.62 0.43 to 0.87	0.59 0.40 to 0.90	0.58 0.16 to 2.26	0.57 0.04 to 5.99	0.49 0.04 to 4.74	0.49 0.20 to 1.14	0.42 0.01 to 6.16	0.42 0.10 to 1.74	0.41 0.24 to 0.71	0.41 0.07 to 1.87	0.40 0.06 to 2.49	0.37 0.09 to 1.55	0.37 0.18 to 0.79	0.32 0.12 to 0.90	0.30 0.14 to 0.65	0.20 0.01 to 3.22	0.14 0.01 to 1.00
VILDAGLIPTIN	0.48 0.01 to 34.67	VILDAGLIPTIN	0.97 0.01 to 93.53	0.56 0.01 to 47.62	0.55 0.01 to 46.99	0.52 0.00 to 43.08	0.52 0.01 to 38.03	0.48 0.01 to 35.70	0.47 0.01 to 36.14	0.44 0.00 to 35.49	0.44 0.00 to 39.42	0.43 0.00 to 38.19	0.38 0.00 to 33.38	0.37 0.00 to 33.82	0.36 0.00 to 27.11	0.35 0.00 to 27.63	0.35 0.00 to 27.25	0.34 0.00 to 28.81	0.30 0.00 to 57.61	0.32 0.00 to 30.53	0.30 0.00 to 21.69	0.30 0.00 to 21.74	0.29 0.00 to 25.01	0.27 0.00 to 37.70	0.23 0.00 to 32.22	0.24 0.00 to 18.82	0.19 0.00 to 28.59	0.21 0.00 to 17.67	0.20 0.00 to 15.46	0.20 0.00 to 17.90	0.20 0.00 to 21.06	0.18 0.00 to 16.43	0.18 0.00 to 14.54	0.16 0.00 to 12.49	0.15 0.00 to 11.38	0.09 0.00 to 18.27	0.06 0.00 to 7.24
CANAGLIFLOZIN	0.50 0.11 to 1.99	1.04 0.01 to 101	CANAGLIFLOZIN	0.57 0.09 to 3.15	0.56 0.10 to 3.13	0.53 0.08 to 3.54	0.52 0.12 to 2.09	0.48 0.11 to 2.00	0.49 0.11 to 2.04	0.45 0.11 to 1.67	0.45 0.06 to 3.12	0.44 0.06 to 2.92	0.40 0.06 to 2.33	0.37 0.05 to 3.06	0.37 0.07 to 1.63	0.36 0.06 to 1.95	0.36 0.07 to 1.71	0.35 0.06 to 2.00	0.32 0.01 to 11.37	0.33 0.04 to 2.36	0.31 0.07 to 1.28	0.30 0.07 to 1.22	0.29 0.04 to 1.94	0.29 0.02 to 4.12	0.24 0.01 to 3.36	0.24 0.04 to 1.19	0.20 0.01 to 4.35	0.21 0.03 to 1.39	0.21 0.05 to 0.82	0.20 0.02 to 1.59	0.20 0.02 to 1.73	0.18 0.03 to 1.21	0.18 0.04 to 0.84	0.16 0.03 to 0.87	0.15 0.03 to 0.66	0.10 0.00 to 2.17	0.07 0.00 to 0.78
SEMA_PO	0.87 0.28 to 2.72	1.79 0.02 to 168	1.75 0.32 to 10.60	SEMA_PO	0.98 0.22 to 4.92	0.94 0.17 to 5.40	0.92 0.28 to 3.02	0.85 0.25 to 2.84	0.85 0.30 to 2.43	0.79 0.22 to 2.95	0.79 0.14 to 4.71	0.76 0.13 to 4.51	0.70 0.12 to 3.58	0.65 0.10 to 4.66	0.65 0.17 to 2.34	0.63 0.13 to 2.79	0.62 0.15 to 2.41	0.62 0.12 to 2.97	0.57 0.01 to 16.28	0.57 0.07 to 5.02	0.55 0.16 to 1.74	0.52 0.16 to 1.65	0.51 0.09 to 2.86	0.50 0.03 to 6.79	0.43 0.03 to 4.96	0.44 0.10 to 1.70	0.36 0.01 to 7.01	0.37 0.06 to 2.04	0.36 0.12 to 1.15	0.36 0.04 to 2.34	0.35 0.04 to 3.03	0.32 0.06 to 1.91	0.32 0.08 to 1.19	0.28 0.06 to 1.27	0.26 0.08 to 0.90	0.17 0.01 to 3.67	0.12 0.01 to 1.14
METFORMIN	0.89 0.27 to 2.63	1.83 0.02 to 174	1.79 0.32 to 10.30	1.02 0.20 to 4.46	METFORMIN	0.94 0.26 to 3.50	0.93 0.30 to 2.72	0.87 0.30 to 2.48	0.87 0.26 to 2.73	0.80 0.22 to 2.87	0.79 0.14 to 4.63	0.78 0.13 to 4.40	0.72 0.13 to 3.41	0.66 0.12 to 3.82	0.65 0.17 to 2.15	0.65 0.13 to 2.72	0.63 0.16 to 2.29	0.63 0.20 to 1.86	0.58 0.01 to 17.33	0.57 0.07 to 4.60	0.56 0.16 to 1.66	0.53 0.16 to 1.61	0.52 0.09 to 2.86	0.52 0.03 to 6.54	0.43 0.03 to 5.66	0.44 0.10 to 1.63	0.36 0.01 to 6.96	0.37 0.09 to 1.46	0.37 0.11 to 1.15	0.36 0.04 to 2.56	0.36 0.04 to 2.94	0.33 0.06 to 1.78	0.33 0.09 to 1.18	0.28 0.07 to 1.24	0.27 0.08 to 0.90	0.17 0.01 to 3.70	0.12 0.01 to 1.16
PIOGLITAZONE	0.95 0.23 to 3.59	1.92 0.02 to 201	1.88 0.28 to 13.04	1.07 0.19 to 5.82	1.07 0.29 to 3.82	PIOGLITAZONE	0.99 0.24 to 3.83	0.92 0.24 to 3.45	0.92 0.22 to 3.78	0.85 0.19 to 3.84	0.83 0.12 to 5.95	0.81 0.12 to 5.51	0.75 0.11 to 4.39	0.69 0.10 to 5.38	0.68 0.15 to 2.89	0.68 0.11 to 3.67	0.66 0.14 to 3.00	0.67 0.18 to 2.33	0.60 0.01 to 18.47	0.60 0.07 to 5.66	0.58 0.13 to 2.27	0.56 0.13 to 2.27	0.55 0.08 to 3.71	0.54 0.03 to 7.95	0.46 0.02 to 6.47	0.46 0.09 to 2.12	0.39 0.01 to 8.49	0.39 0.08 to 1.73	0.39 0.10 to 1.54	0.38 0.04 to 3.06	0.38 0.04 to 3.69	0.34 0.05 to 2.37	0.34 0.07 to 1.60	0.29 0.06 to 1.62	0.28 0.07 to 1.26	0.18 0.00 to 4.21	0.13 0.01 to 1.42
LIRA_SC	0.96 0.53 to 1.69	1.93 0.03 to 166	1.91 0.48 to 8.35	1.08 0.33 to 3.59	1.07 0.37 to 3.28	1.01 0.26 to 4.10	LIRA_SC	0.93 0.55 to 1.61	0.93 0.51 to 1.70	0.86 0.40 to 1.95	0.85 0.20 to 3.84	0.84 0.19 to 3.52	0.76 0.20 to 2.81	0.71 0.15 to 3.86	0.70 0.30 to 1.50	0.69 0.20 to 2.21	0.68 0.28 to 1.58	0.67 0.21 to 2.23	0.62 0.01 to 15.68	0.61 0.11 to 3.88	0.59 0.30 to 1.12	0.57 0.30 to 1.05	0.55 0.14 to 2.32	0.54 0.04 to 6.04	0.47 0.03 to 4.71	0.47 0.16 to 1.22	0.40 0.01 to 6.15	0.41 0.09 to 1.63	0.39 0.22 to 0.70	0.39 0.06 to 2.04	0.39 0.06 to 2.46	0.35 0.09 to 1.26	0.35 0.15 to 0.81	0.30 0.11 to 0.91	0.29 0.14 to 0.58	0.19 0.01 to 3.35	0.13 0.01 to 1.06
SITAGLIPTIN	1.03 0.55 to 1.82	2.09 0.03 to 170	2.07 0.50 to 9.30	1.17 0.35 to 4.00	1.16 0.40 to 3.33	1.09 0.29 to 4.14	1.08 0.62 to 1.81	SITAGLIPTIN	1.00 0.52 to 1.91	0.93 0.40 to 2.15	0.91 0.22 to 4.12	0.90 0.20 to 3.74	0.83 0.20 to 2.87	0.76 0.16 to 4.22	0.76 0.35 to 1.50	0.74 0.21 to 2.37	0.73 0.29 to 1.76	0.73 0.23 to 2.24	0.67 0.01 to 16.80	0.66 0.11 to 4.42	0.64 0.31 to 1.19	0.61 0.32 to 1.13	0.60 0.14 to 2.54	0.59 0.04 to 6.38	0.50 0.04 to 5.20	0.51 0.18 to 1.27	0.43 0.01 to 6.80	0.44 0.11 to 1.64	0.43 0.23 to 0.75	0.41 0.06 to 2.23	0.42 0.06 to 2.66	0.38 0.09 to 1.56	0.38 0.15 to 0.90	0.32 0.11 to 1.01	0.31 0.15 to 0.62	0.20 0.01 to 3.54	0.15 0.01 to 1.11
DULA_SC	1.03 0.57 to 1.75	2.11 0.03 to 177	2.05 0.49 to 9.30	1.18 0.41 to 3.30	1.15 0.37 to 3.86	1.09 0.26 to 4.53	1.08 0.59 to 1.97	1.00 0.52 to 1.93	DULA_SC	0.93 0.43 to 2.08	0.91 0.22 to 4.09	0.91 0.20 to 3.79	0.82 0.20 to 2.91	0.75 0.15 to 4.35	0.76 0.31 to 1.65	0.74 0.22 to 2.32	0.73 0.29 to 1.82	0.73 0.21 to 2.44	0.68 0.01 to 16.87	0.66 0.11 to 4.43	0.64 0.31 to 1.18	0.62 0.32 to 1.12	0.61 0.15 to 2.46	0.58 0.04 to 6.07	0.50 0.04 to 4.77	0.51 0.18 to 1.30	0.43 0.01 to 6.55	0.43 0.10 to 1.76	0.43 0.25 to 0.70	0.42 0.06 to 2.09	0.42 0.06 to 2.65	0.38 0.09 to 1.56	0.38 0.16 to 0.91	0.32 0.11 to 0.99	0.31 0.15 to 0.60	0.20 0.01 to 3.55	0.15 0.01 to 1.11
SEMA_SC	1.12 0.50 to 2.19	2.27 0.03 to 202	2.20 0.60 to 8.80	1.27 0.34 to 4.56	1.25 0.35 to 4.57	1.18 0.26 to 5.28	1.16 0.51 to 2.50	1.08 0.46 to 2.48	1.08 0.48 to 2.34	SEMA_SC	1.00 0.21 to 4.64	0.97 0.20 to 4.36	0.90 0.20 to 3.32	0.81 0.15 to 4.88	0.82 0.30 to 2.02	0.80 0.21 to 2.66	0.79 0.28 to 2.11	0.79 0.20 to 2.92	0.72 0.01 to 18.93	0.71 0.12 to 4.77	0.69 0.29 to 1.45	0.66 0.29 to 1.39	0.65 0.14 to 2.75	0.64 0.05 to 6.09	0.55 0.04 to 5.71	0.55 0.17 to 1.51	0.46 0.01 to 7.67	0.47 0.10 to 2.08	0.46 0.21 to 0.94	0.45 0.06 to 2.41	0.45 0.07 to 2.55	0.41 0.09 to 1.81	0.41 0.15 to 1.09	0.35 0.11 to 1.15	0.33 0.13 to 0.82	0.22 0.01 to 3.91	0.16 0.01 to 1.23
BEIN_SC	1.12 0.25 to 4.56	2.27 0.03 to 233	2.24 0.32 to 16.31	1.27 0.21 to 7.24	1.27 0.22 to 7.31	1.21 0.17 to 8.00	1.18 0.26 to 4.91	1.09 0.24 to 4.57	1.10 0.24 to 4.45	1.00 0.22 to 4.75	BEIN_SC	0.98 0.14 to 6.79	0.89 0.13 to 5.40	0.82 0.09 to 7.37	0.82 0.16 to 3.71	0.79 0.13 to 4.47	0.79 0.15 to 3.82	0.79 0.13 to 4.82	0.74 0.01 to 22.75	0.72 0.07 to 7.22	0.69 0.15 to 2.87	0.67 0.15 to 2.74	0.65 0.09 to 4.55	0.62 0.03 to 9.97	0.55 0.03 to 7.46	0.55 0.10 to 2.79	0.45 0.01 to 9.74	0.47 0.07 to 3.29	0.46 0.11 to 1.71	0.45 0.05 to 3.58	0.44 0.04 to 4.32	0.42 0.06 to 2.77	0.41 0.08 to 1.99	0.36 0.06 to 2.03	0.34 0.07 to 1.44	0.22 0.01 to 5.35	0.16 0.01 to 1.76
ROSIGLITAZONE	1.16 0.29 to 4.48	2.33 0.03 to 218	2.27 0.34 to 16.40	1.31 0.22 to 7.53	1.29 0.23 to 7.70	1.24 0.18 to 8.32	1.19 0.28 to 5.28	1.11 0.27 to 4.97	1.10 0.26 to 4.91	1.03 0.23 to 4.88	1.02 0.15 to 7.27	ROSIGLITAZONE	0.93 0.15 to 4.94	0.86 0.10 to 7.58	0.84 0.19 to 3.59	0.82 0.14 to 4.48	0.80 0.18 to 3.78	0.81 0.13 to 5.10	0.73 0.01 to 23.36	0.73 0.08 to 7.83	0.71 0.17 to 2.85	0.69 0.18 to 2.53	0.67 0.17 to 2.51	0.64 0.04 to 9.89	0.56 0.03 to 7.83	0.57 0.12 to 2.49	0.47 0.01 to 9.82	0.48 0.07 to 3.48	0.47 0.11 to 1.99	0.47 0.05 to 3.55	0.46 0.05 to 4.21	0.43 0.06 to 3.07	0.42 0.09 to 1.85	0.36 0.07 to 1.96	0.34 0.07 to 1.64	0.22 0.01 to 4.99	0.16 0.01 to 1.83
IGLARLIXI_SC	1.25 0.37 to 4.45	2.62 0.03 to 252	2.48 0.43 to 17.49	1.42 0.28 to 8.17	1.39 0.29 to 7.81	1.33 0.23 to 9.12	1.31 0.36 to 5.12	1.21 0.35 to 4.91	1.21 0.34 to 4.90	1.12 0.30 to 5.11	1.12 0.19 to 7.56	1.08 0.20 to 6.72	IGLARLIXI_SC	0.93 0.13 to 7.82	0.91 0.25 to 3.62	0.90 0.18 to 4.68	0.88 0.23 to 3.78	0.88 0.17 to 5.04	0.82 0.02 to 26.20	0.81 0.09 to 8.05	0.78 0.22 to 2.80	0.74 0.24 to 2.54	0.73 0.13 to 4.39	0.70 0.04 to 10.44	0.62 0.04 to 7.81	0.62 0.25 to 1.52	0.54 0.02 to 10.10	0.53 0.08 to 3.53	0.51 0.15 to 1.98	0.51 0.06 to 3.91	0.50 0.05 to 4.71	0.47 0.07 to 2.94	0.46 0.12 to 1.88	0.39 0.09 to 1.97	0.37 0.10 to 1.59	0.25 0.01 to 5.46	0.18 0.01 to 1.85
LIRAMETF_SC	1.35 0.24 to 6.60	2.72 0.03 to 318	2.69 0.33 to 21.69	1.53 0.21 to 10.40	1.52 0.26 to 8.41	1.45 0.19 to 10.22	1.41 0.26 to 6.56	1.32 0.24 to 6.34	1.33 0.23 to 6.60	1.23 0.20 to 6.60	1.22 0.14 to 10.58	1.16 0.13 to 9.61	1.08 0.13 to 7.65	LIRAMETF_SC	0.99 0.16 to 5.14	0.97 0.13 to 6.35	0.96 0.15 to 5.32	0.95 0.13 to 6.00	0.85 0.01 to 31.52	0.87 0.07 to 9.45	0.83 0.14 to 4.14	0.81 0.14 to 3.94	0.79 0.09 to 6.15	0.78 0.04 to 12.82	0.66 0.03 to 10.07	0.66 0.09 to 3.76	0.56 0.01 to 12.93	0.56 0.07 to 4.06	0.56 0.10 to 2.77	0.54 0.05 to 5.21	0.53 0.04 to 6.19	0.49 0.06 to 3.66	0.50 0.08 to 2.76	0.43 0.06 to 2.68	0.41 0.07 to 2.16	0.26 0.01 to 7.24	0.18 0.01 to 2.57
TASP_SC	1.36 0.70 to 2.74	2.80 0.04 to 240	2.73 0.61 to 13.49	1.55 0.43 to 6.00	1.53 0.47 to 5.72	1.46 0.35 to 6.69	1.42 0.67 to 3.30	1.32 0.67 to 2.86	1.31 0.61 to 3.18	1.22 0.50 to 3.33	1.22 0.27 to 6.15	1.19 0.28 to 5.27	1.10 0.28 to 4.00	1.01 0.19 to 6.35	TASP_SC	0.98 0.28 to 3.27	0.97 0.38 to 2.61	0.96 0.27 to 3.63	0.90 0.02 to 22.73	0.87 0.14 to 6.46	0.85 0.40 to 1.70	0.81 0.43 to 1.61	0.79 0.19 to 3.36	0.78 0.05 to 9.39	0.67 0.05 to 7.29	0.68 0.23 to 1.77	0.58 0.02 to 9.06	0.57 0.13 to 2.72	0.56 0.26 to 1.27	0.55 0.08 to 2.96	0.55 0.07 to 3.78	0.51 0.10 to 2.37	0.50 0.20 to 1.32	0.43 0.14 to 1.39	0.41 0.17 to 1.08	0.27 0.01 to 5.09	0.19 0.01 to 1.56
VISEPE_SC	1.39 0.51 to 3.96	2.87 0.04 to 263	2.76 0.51 to 17.45	1.59 0.36 to 7.45	1.55 0.37 to 7.87	1.48 0.27 to 8.83	1.46 0.45 to 4.98	1.35 0.42 to 4.65	1.35 0.43 to 4.54	1.25 0.38 to 4.69	1.26 0.22 to 7.74	1.21 0.22 to 7.12	1.11 0.21 to 5.44	1.03 0.16 to 7.64	1.02 0.31 to 3.57	VISEPE_SC	0.98 0.28 to 3.81	0.97 0.21 to 4.83	0.92 0.02 to 27.14	0.90 0.12 to 7.91	0.86 0.30 to 2.55	0.83 0.29 to 2.55	0.82 0.16 to 4.50	0.80 0.05 to 11.18	0.68 0.04 to 8.67	0.68 0.18 to 2.55	0.58 0.02 to 10.77	0.58 0.11 to 3.33	0.57 0.18 to 1.94	0.56 0.07 to 3.88	0.57 0.06 to 4.63	0.52 0.09 to 3.08	0.51 0.14 to 1.97	0.44 0.11 to 2.05	0.42 0.12 to 1.54	0.28 0.01 to 5.50	0.19 0.01 to 1.84
ALBI_SC	1.42 0.64 to 3.06	2.88 0.04 to 234	2.79 0.59 to 14.36	1.60 0.42 to 6.47	1.58 0.44 to 6.13	1.52 0.33 to 7.07	1.47 0.63 to 3.52	1.37 0.57 to 3.47	1.38 0.55 to 3.41	1.27 0.47 to 3.62	1.27 0.26 to 6.53	1.25 0.26 to 5.64	1.14 0.26 to 4.38	1.04 0.19 to 6.53	1.03 0.38 to 2.65	1.02 0.26 to 3.56	ALBI_SC	1.00 0.25 to 4.01	0.94 0.02 to 24.40	0.91 0.14 to 6.84	0.88 0.37 to 1.96	0.84 0.38 to 1.87	0.83 0.18 to 3.66	0.81 0.05 to 9.07	0.69 0.05 to 7.61	0.70 0.22 to 1.98	0.59 0.02 to 9.33	0.59 0.12 to 2.80	0.58 0.24 to 1.40	0.58 0.08 to 3.16	0.57 0.07 to 4.24	0.52 0.11 to 2.41	0.52 0.24 to 1.08	0.45 0.15 to 1.38	0.42 0.15 to 1.16	0.28 0.01 to 5.33	0.20 0.01 to 1.74
EXENER_SC	1.43 0.43 to 4.59	2.90 0.03 to 294	2.83 0.50 to 17.62	1.61 0.34 to 8.05	1.59 0.54 to 5.10	1.49 0.43 to 5.67	1.49 0.45 to 4.87	1.37 0.45 to 4.28	1.38 0.41 to 4.80	1.27 0.34 to 4.94	1.26 0.21 to 7.63	1.24 0.20 to 7.65	1.14 0.20 to 5.93	1.06 0.17 to 7.57	1.04 0.28 to 3.76	1.03 0.21 to 4.73	1.00 0.25 to 4.01	EXENER_SC	0.91 0.02 to 27.26	0.91 0.11 to 8.28	0.88 0.25 to 2.86	0.84 0.24 to 2.84	0.83 0.14 to 5.04	0.82 0.05 to 10.93	0.68 0.04 to 9.40	0.70 0.16 to 2.85	0.59 0.02 to 11.58	0.59 0.24 to 1.45	0.58 0.17 to 1.97	0.57 0.07 to 4.09	0.57 0.06 to 4.90	0.52 0.09 to 3.05	0.52 0.13 to 2.07	0.45 0.10 to 2.02	0.42 0.12 to 1.56	0.28 0.01 to 5.89	0.19 0.01 to 1.94
ORFO_PO	1.52 0.07 to 68.91	3.32 0.02 to 1030	3.09 0.09 to 186	1.76 0.06 to 98.38	1.73 0.06 to 90.45	1.67 0.05 to 98.77	1.61 0.06 to 77.61	1.49 0.06 to 73.90	1.47 0.06 to 71.23	1.39 0.05 to 68.69	1.35 0.04 to 88.93	1.37 0.04 to 79.59	1.22 0.04 to 65.43	1.17 0.03 to 70.80	1.11 0.04 to 52.99	1.09 0.04 to 57.17	1.07 0.04 to 54.91	1.10 0.04 to 61.40	ORFO_PO	1.02 0.02 to 63.41	0.95 0.04 to 44.17	0.91 0.04 to 42.19	0.89 0.03 to 51.23	0.90 0.01 to 78.61	0.74 0.01 to 67.80	0.75 0.03 to 38.27	0.62 0.01 to 71.84	0.64 0.02 to 37.54	0.62 0.03 to 30.90	0.61 0.01 to 40.19	0.63 0.01 to 40.89	0.57 0.02 to 33.65	0.57 0.02 to 28.47	0.49 0.02 to 27.10	0.47 0.02 to 22.91	0.30 0.00 to 33.64	0.21 0.00 to 15.63
CANALIRA_SC	1.55 0.24 to 9.52	3.12 0.03 to 359	3.07 0.42 to 23.20	1.76 0.20 to 13.77	1.76 0.22 to 13.79	1.66 0.18 to 14.34	1.63 0.26 to 9.51	1.51 0.23 to 9.39	1.52 0.23 to 9.50	1.40 0.21 to 8.51	1.39 0.14 to 13.75	1.38 0.13 to 13.04	1.24 0.12 to 10.80	1.15 0.11 to 13.41	1.15 0.15 to 7.21	1.11 0.13 to 8.54	1.09 0.15 to 7.26	1.10 0.12 to 8.82	0.98 0.02 to 41.18	CANALIRA_SC	0.96 0.14 to 5.93	0.92 0.13 to 5.54	0.90 0.09 to 8.34	0.88 0.04 to 16.51	0.74 0.03 to 13.04	0.76 0.09 to 5.54	0.61 0.02 to 16.69	0.64 0.06 to 5.95	0.64 0.10 to 3.89	0.62 0.05 to 6.76	0.63 0.05 to 7.23	0.58 0.06 to 4.97	0.57 0.08 to 3.84	0.49 0.06 to 3.91	0.47 0.06 to 3.10	0.30 0.01 to 8.29	0.21 0.01 to 3.18
LIXI_SC	1.61 1.14 to 2.34	3.34 0.05 to 266	3.23 0.78 to 14.84	1.83 0.57 to 6.27	1.80 0.60 to 6.30	1.72 0.44 to 7.41	1.68 0.89 to 3.38	1.56 0.84 to 3.22	1.56 0.85 to 3.20	1.46 0.69 to 3.45	1.44 0.35 to 6.89	1.41 0.35 to 5.96	1.29 0.36 to 4.47	1.20 0.24 to 6.96	1.18 0.59 to 2.48	1.16 0.39 to 3.37	1.14 0.51 to 2.71	1.14 0.35 to 4.02	1.06 0.02 to 24.96	1.04 0.17 to 7.24	LIXI_SC	0.96 0.59 to 1.62	0.94 0.24 to 3.91	0.92 0.07 to 10.10	0.80 0.06 to 8.15	0.79 0.31 to 1.94	0.68 0.02 to 10.08	0.68 0.16 to 2.91	0.66 0.36 to 1.28	0.66 0.11 to 3.27	0.65 0.09 to 4.20	0.60 0.13 to 2.57	0.59 0.27 to 1.37	0.51 0.18 to 1.56	0.48 0.22 to 1.11	0.32 0.01 to 5.29	0.23 0.02 to 1.67
EXEN_SC	1.68 1.11 to 2.50	3.39 0.05 to 282	3.37 0.82 to 14.97	1.92 0.61 to 6.32	1.88 0.62 to 6.29	1.78 0.44 to 7.54	1.74 0.95 to 3.39	1.63 0.88 to 3.16	1.62 0.90 to 3.10	1.51 0.72 to 3.50	1.49 0.37 to 6.87	1.45 0.40 to 5.64	1.35 0.39 to 4.18	1.24 0.25 to 7.22	1.23 0.62 to 2.32	1.20 0.39 to 3.48	1.19 0.54 to 2.64	1.19 0.35 to 4.10	1.09 0.02 to 26.77	1.08 0.18 to 7.65	1.04 0.62 to 1.69	EXEN_SC	0.97 0.27 to 3.63	0.95 0.07 to 10.42	0.81 0.06 to 8.04	0.83 0.36 to 1.73	0.71 0.02 to 10.56	0.71 0.17 to 3.01	0.69 0.40 to 1.22	0.69 0.11 to 3.33	0.67 0.10 to 4.26	0.62 0.14 to 2.67	0.62 0.30 to 1.25	0.53 0.20 to 1.48	0.50 0.23 to 1.13	0.33 0.01 to 5.70	0.23 0.02 to 1.81
EXENROSI_SC	1.72 0.44 to 6.43	3.45 0.04 to 338	3.42 0.52 to 24.89	1.95 0.35 to 10.98	1.94 0.35 to 11.48	1.83 0.27 to 12.30	1.81 0.43 to 7.38	1.67 0.39 to 7.10	1.65 0.41 to 6.87	1.54 0.36 to 6.97	1.53 0.22 to 10.85	1.48 0.40 to 5.80	1.38 0.23 to 7.47	1.26 0.16 to 10.88	1.26 0.30 to 5.15	1.22 0.22 to 6.40	1.21 0.27 to 5.47	1.21 0.20 to 7.35	1.12 0.02 to 33.24	1.11 0.12 to 11.53	1.06 0.26 to 4.15	1.03 0.28 to 3.66	EXENROSI_SC	0.97 0.06 to 15.23	0.83 0.05 to 11.95	0.84 0.18 to 3.74	0.71 0.02 to 14.11	0.72 0.10 to 4.83	0.71 0.18 to 2.95	0.69 0.08 to 5.12	0.68 0.07 to 6.31	0.63 0.09 to 4.32	0.63 0.14 to 2.70	0.55 0.11 to 2.74	0.51 0.11 to 2.31	0.33 0.01 to 7.80	0.24 0.01 to 2.75
TIRZ_SC	1.75 0.17 to 23.12	3.67 0.03 to 575	3.48 0.24 to 62.74	2.00 0.15 to 33.03	1.93 0.15 to 32.60	1.84 0.13 to 33.95	1.84 0.17 to 25.24	1.70 0.16 to 22.59	1.71 0.16 to 23.62	1.55 0.16 to 20.28	1.60 0.10 to 30.81	1.56 0.10 to 27.56	1.43 0.10 to 22.90	1.29 0.08 to 28.50	1.28 0.11 to 18.63	1.26 0.09 to 21.07	1.24 0.11 to 18.61	1.22 0.09 to 20.90	1.11 0.01 to 67.25	1.14 0.06 to 25.49	1.09 0.10 to 14.61	1.05 0.10 to 14.11	1.03 0.07 to 17.71	TIRZ_SC	0.86 0.03 to 24.50	0.87 0.07 to 12.47	0.73 0.01 to 30.71	0.74 0.04 to 13.48	0.72 0.07 to 9.65	0.71 0.04 to 14.32	0.71 0.04 to 13.61	0.65 0.04 to 12.26	0.64 0.05 to 9.07	0.56 0.04 to 9.07	0.52 0.05 to 7.53	0.35 0.01 to 15.69	0.24 0.01 to 6.56
EMPAGLIFLOZIN	2.03 0.21 to 26.09	4.37 0.03 to 660	4.15 0.30 to 75.99	2.33 0.20 to 35.73	2.32 0.18 to 37.14	2.18 0.15 to 40.78	2.14 0.21 to 28.85	1.99 0.19 to 27.80	1.99 0.21 to 26.18	1.83 0.18 to 26.00	1.83 0.13 to 32.49	1.80 0.13 to 32.48	1.61 0.13 to 26.31	1.52 0.10 to 33.99	1.48 0.14 to 20.08	1.47 0.12 to 22.89	1.45 0.13 to 21.77	1.47 0.11 to 23.50	1.34 0.01 to 82.85	1.35 0.08 to 29.75	1.25 0.12 to 16.39	1.23 0.12 to 16.85	1.20 0.08 to 20.64	1.16 0.04 to 35.58	EMPAGLIFLOZIN	0.98 0.09 to 14.85	0.83 0.01 to 33.79	0.87 0.06 to 15.80	0.85 0.08 to 11.05	0.84 0.04 to 16.38	0.83 0.04 to 16.95	0.76 0.05 to 14.34	0.74 0.07 to 10.52	0.66 0.06 to 9.33	0.61 0.06 to 8.64	0.40 0.01 to 19.10	0.28 0.01 to 7.21
INS_PREMIX	2.04 0.87 to 4.99	4.21 0.05 to 363	4.09 0.84 to 22.56	2.30 0.59 to 10.11	2.27 0.61 to 10.14	2.19 0.47 to 11.45	2.14 0.82 to 6.17	1.96 0.78 to 5.61	1.98 0.77 to 5.57	1.82 0.66 to 6.00	1.82 0.36 to 10.39	1.77 0.40 to 8.45	1.62 0.66 to 3.97	1.51 0.27 to 10.64	1.47 0.56 to 4.29	1.46 0.39 to 5.55	1.42 0.51 to 4.49	1.43 0.35 to 6.37	1.34 0.03 to 35.88	1.31 0.18 to 10.65	1.27 0.51 to 3.19	1.21 0.58 to 2.82	1.19 0.27 to 5.58	1.15 0.08 to 14.63	1.02 0.07 to 11.32	INS_PREMIX	0.87 0.03 to 14.00	0.85 0.17 to 4.65	0.84 0.33 to 2.28	0.84 0.11 to 5.00	0.81 0.10 to 6.37	0.76 0.15 to 4.04	0.74 0.27 to 2.16	0.65 0.18 to 2.42	0.61 0.22 to 1.91	0.41 0.01 to 8.08	0.29 0.02 to 2.59
EFPE_SC	2.35 0.16 to 70.68	5.37 0.03 to 1152	4.88 0.23 to 180	2.77 0.14 to 87.83	2.78 0.14 to 99.78	2.60 0.12 to 93.64	2.49 0.16 to 77.95	2.32 0.15 to 75.38	2.33 0.15 to 71.75	2.15 0.13 to 69.50	2.23 0.10 to 81.88	2.13 0.10 to 82.07	1.86 0.10 to 64.89	1.80 0.08 to 77.45	1.74 0.11 to 56.09	1.72 0.09 to 57.75	1.70 0.11 to 50.95	1.70 0.09 to 57.32	1.62 0.01 to 146	1.63 0.06 to 64.15	1.47 0.10 to 43.32	1.41 0.09 to 42.75	1.41 0.07 to 54.30	1.37 0.03 to 80.36	1.21 0.03 to 70.93	1.15 0.07 to 37.05	EFPE_SC	1.00 0.05 to 36.93	0.98 0.06 to 29.38	0.97 0.04 to 37.57	0.97 0.03 to 44.36	0.91 0.04 to 32.98	0.87 0.06 to 26.70	0.76 0.04 to 24.20	0.73 0.05 to 21.25	0.48 0.01 to 35.05	0.34 0.01 to 16.74
OTHER_ACTIVE_basal_bolus_insulin	2.37 0.57 to 9.85	4.83 0.06 to 517	4.75 0.72 to 35.30	2.70 0.49 to 15.57	2.70 0.69 to 10.84	2.58 0.58 to 12.28	2.46 0.61 to 10.55	2.29 0.61 to 9.28	2.31 0.57 to 10.11	2.13 0.48 to 10.44	2.11 0.30 to 15.16	2.08 0.29 to 14.73	1.90 0.28 to 12.11	1.79 0.25 to 14.61	1.76 0.37 to 7.98	1.73 0.30 to 9.36	1.69 0.36 to 8.65	1.69 0.69 to 4.15	1.56 0.03 to 52.13	1.56 0.17 to 16.35	1.48 0.34 to 6.14	1.42 0.33 to 6.01	1.39 0.21 to 9.59	1.36 0.07 to 22.26	1.16 0.06 to 17.87	1.17 0.22 to 5.92	1.00 0.03 to 20.46	OTHER_ACTIVE_basal_bolus_insulin	0.98 0.24 to 4.24	0.95 0.10 to 8.61	0.94 0.09 to 9.06	0.88 0.13 to 6.09	0.87 0.19 to 4.38	0.75 0.14 to 4.33	0.71 0.16 to 3.23	0.47 0.01 to 10.89	0.33 0.02 to 3.74
INS_GLARGINE	2.43 1.41 to 4.10	4.96 0.06 to 399	4.84 1.21 to 21.40	2.76 0.87 to 8.60	2.74 0.87 to 8.83	2.59 0.65 to 10.42	2.54 1.43 to 4.53	2.35 1.32 to 4.40	2.35 1.42 to 4.01	2.18 1.07 to 4.69	2.16 0.58 to 8.92	2.13 0.50 to 8.79	1.95 0.50 to 6.74	1.79 0.36 to 10.22	1.78 0.79 to 3.82	1.75 0.51 to 5.51	1.72 0.72 to 4.17	1.71 0.51 to 5.82	1.60 0.03 to 39.52	1.55 0.26 to 10.39	1.51 0.78 to 2.74	1.45 0.82 to 2.52	1.42 0.34 to 5.65	1.38 0.10 to 14.80	1.18 0.09 to 12.15	1.19 0.44 to 3.00	1.02 0.03 to 16.03	1.02 0.24 to 4.11	INS_GLARGINE	0.98 0.15 to 5.01	0.98 0.14 to 6.40	0.89 0.21 to 3.70	0.89 0.38 to 2.06	0.77 0.27 to 2.28	0.73 0.37 to 1.46	0.48 0.02 to 8.32	0.34 0.02 to 2.62
HRS7535_PO	2.43 0.53 to 15.12	5.12 0.06 to 545	4.95 0.63 to 48.20	2.81 0.43 to 22.86	2.78 0.39 to 23.16	2.64 0.33 to 26.57	2.59 0.49 to 17.43	2.43 0.45 to 16.34	2.39 0.48 to 15.65	2.22 0.41 to 15.44	2.23 0.28 to 22.00	2.14 0.28 to 21.30	1.97 0.26 to 17.37	1.87 0.19 to 21.14	1.80 0.34 to 11.85	1.78 0.26 to 13.62	1.73 0.32 to 12.52	1.77 0.24 to 14.67	1.64 0.02 to 68.14	1.61 0.15 to 22.08	1.51 0.31 to 9.45	1.46 0.30 to 9.48	1.45 0.20 to 13.28	1.42 0.07 to 28.18	1.19 0.06 to 22.65	1.19 0.20 to 9.13	1.04 0.03 to 25.36	1.06 0.12 to 10.36	1.02 0.20 to 6.72	HRS7535_PO	1.01 0.09 to 11.85	0.93 0.11 to 8.96	0.91 0.16 to 6.29	0.79 0.13 to 6.25	0.73 0.13 to 5.32	0.50 0.01 to 14.66	0.35 0.02 to 5.18
INS_ASPART	2.50 0.40 to 16.81	5.09 0.05 to 600	5.02 0.58 to 46.91	2.87 0.33 to 24.43	2.80 0.34 to 25.50	2.66 0.27 to 28.38	2.59 0.41 to 18.14	2.39 0.38 to 17.35	2.38 0.38 to 16.95	2.23 0.39 to 13.91	2.29 0.23 to 23.52	2.19 0.24 to 22.20	1.99 0.21 to 18.37	1.90 0.16 to 22.56	1.81 0.26 to 13.75	1.76 0.22 to 16.17	1.75 0.24 to 13.73	1.76 0.20 to 16.07	1.58 0.02 to 67.11	1.60 0.14 to 21.47	1.53 0.24 to 10.66	1.49 0.23 to 10.45	1.47 0.16 to 14.67	1.41 0.07 to 26.48	1.20 0.06 to 23.64	1.23 0.16 to 9.83	1.03 0.02 to 29.69	1.06 0.11 to 10.68	1.02 0.16 to 7.05	0.99 0.08 to 11.08	INS_ASPART	0.92 0.10 to 9.39	0.92 0.13 to 6.79	0.78 0.10 to 7.05	0.74 0.11 to 5.59	0.49 0.01 to 14.73	0.35 0.01 to 5.59
OTHER_ACTIVE_insulin_dose_increase	2.70 0.64 to 11.31	5.51 0.06 to 583	5.44 0.83 to 38.45	3.09 0.52 to 17.84	3.06 0.56 to 17.30	2.90 0.42 to 19.71	2.84 0.79 to 10.67	2.63 0.64 to 11.35	2.61 0.64 to 11.38	2.45 0.55 to 11.31	2.40 0.36 to 17.74	2.34 0.33 to 16.82	2.14 0.34 to 13.73	2.03 0.27 to 16.91	1.96 0.42 to 9.84	1.93 0.33 to 10.87	1.91 0.42 to 9.40	1.91 0.33 to 11.35	1.77 0.03 to 59.20	1.74 0.20 to 17.46	1.67 0.39 to 7.44	1.61 0.37 to 7.13	1.59 0.23 to 10.77	1.54 0.08 to 23.40	1.32 0.07 to 19.37	1.32 0.25 to 6.84	1.10 0.03 to 23.32	1.14 0.16 to 7.68	1.12 0.27 to 4.74	1.08 0.11 to 9.05	1.08 0.11 to 10.17	OTHER_ACTIVE_insulin_dose_increase	0.99 0.21 to 4.80	0.85 0.16 to 4.91	0.81 0.18 to 3.59	0.52 0.01 to 12.09	0.37 0.02 to 4.48
INS_LISPRO	2.73 1.27 to 5.64	5.53 0.07 to 472	5.44 1.19 to 27.14	3.11 0.84 to 12.06	3.03 0.85 to 11.75	2.93 0.63 to 13.56	2.84 1.24 to 6.81	2.64 1.11 to 6.59	2.65 1.10 to 6.40	2.45 0.92 to 6.75	2.43 0.50 to 12.73	2.37 0.54 to 10.77	2.18 0.53 to 8.08	1.99 0.36 to 13.19	2.00 0.76 to 4.91	1.98 0.51 to 6.95	1.93 0.93 to 4.09	1.94 0.48 to 7.64	1.76 0.04 to 45.91	1.75 0.26 to 13.00	1.69 0.73 to 3.67	1.62 0.80 to 3.31	1.58 0.37 to 7.00	1.56 0.11 to 18.19	1.34 0.10 to 14.04	1.34 0.46 to 3.64	1.15 0.04 to 18.07	1.14 0.23 to 5.28	1.12 0.48 to 2.60	1.10 0.16 to 6.09	1.09 0.15 to 7.49	1.01 0.21 to 4.75	INS_LISPRO	0.87 0.33 to 2.35	0.82 0.30 to 2.16	0.54 0.02 to 9.77	0.38 0.02 to 3.22
STANDARD_CARE	3.14 1.11 to 8.55	6.43 0.08 to 604	6.35 1.15 to 36.01	3.63 0.79 to 15.92	3.56 0.81 to 15.29	3.39 0.62 to 17.98	3.33 1.10 to 9.39	3.08 0.99 to 9.19	3.08 1.01 to 9.14	2.87 0.87 to 9.13	2.79 0.49 to 15.60	2.76 0.51 to 14.17	2.54 0.51 to 11.37	2.34 0.37 to 16.14	2.30 0.72 to 6.92	2.27 0.49 to 9.19	2.23 0.72 to 6.77	2.22 0.50 to 9.93	2.04 0.04 to 61.82	2.05 0.26 to 16.36	1.95 0.64 to 5.49	1.87 0.68 to 4.97	1.83 0.36 to 8.94	1.78 0.11 to 22.64	1.53 0.11 to 17.57	1.54 0.41 to 5.42	1.31 0.04 to 22.25	1.33 0.23 to 7.09	1.31 0.44 to 3.70	1.27 0.16 to 7.89	1.28 0.14 to 9.85	1.18 0.20 to 6.33	1.15 0.43 to 3.02	STANDARD_CARE	0.95 0.28 to 2.99	0.62 0.02 to 12.90	0.44 0.03 to 4.11
GLIMEPIRIDE	3.34 1.54 to 6.91	6.70 0.09 to 612	6.59 1.52 to 31.72	3.82 1.11 to 13.30	3.76 1.11 to 12.62	3.53 0.79 to 15.25	3.48 1.71 to 6.99	3.24 1.60 to 6.73	3.23 1.66 to 6.50	3.00 1.23 to 7.76	2.97 0.70 to 14.04	2.93 0.61 to 13.45	2.70 0.63 to 10.21	2.44 0.46 to 15.35	2.46 0.93 to 6.01	2.38 0.65 to 8.24	2.37 0.86 to 6.51	2.36 0.64 to 8.50	2.15 0.04 to 56.23	2.13 0.32 to 15.42	2.08 0.90 to 4.54	2.00 0.89 to 4.28	1.95 0.43 to 8.82	1.93 0.13 to 21.83	1.63 0.12 to 16.70	1.65 0.52 to 4.53	1.37 0.05 to 21.70	1.41 0.31 to 6.27	1.37 0.69 to 2.72	1.37 0.19 to 7.53	1.35 0.18 to 8.96	1.23 0.28 to 5.42	1.22 0.46 to 3.29	1.06 0.33 to 3.57	GLIMEPIRIDE	0.67 0.02 to 12.15	0.47 0.03 to 3.79
MAZD_SC	5.02 0.31 to 151	10.71 0.05 to 2523	10.13 0.46 to 391	5.77 0.27 to 179	5.72 0.27 to 200	5.44 0.24 to 201	5.28 0.30 to 159	4.96 0.28 to 152	4.92 0.28 to 144	4.62 0.26 to 148	4.60 0.19 to 182	4.48 0.20 to 157	4.00 0.18 to 142	3.84 0.14 to 154	3.65 0.20 to 107	3.57 0.18 to 127	3.57 0.19 to 119	3.57 0.17 to 139	3.31 0.03 to 348	3.34 0.12 to 144	3.09 0.19 to 96.86	3.04 0.18 to 90.96	3.00 0.13 to 112	2.88 0.06 to 166	2.52 0.05 to 138	2.44 0.12 to 79.88	2.10 0.03 to 152	2.12 0.09 to 85.99	2.08 0.12 to 61.80	2.01 0.07 to 85.05	2.03 0.07 to 91.42	1.92 0.08 to 67.63	1.85 0.10 to 60.25	1.61 0.08 to 52.17	1.49 0.08 to 47.25	MAZD_SC	0.69 0.01 to 34.34
DANU_PO	7.07 1.00 to 101	15.40 0.14 to 2402	14.43 1.29 to 293	8.05 0.87 to 148	8.14 0.86 to 140	7.81 0.70 to 142	7.47 0.95 to 113	6.84 0.90 to 102	6.82 0.90 to 109	6.39 0.81 to 105	6.43 0.57 to 133	6.41 0.55 to 129	5.68 0.54 to 105	5.45 0.39 to 129	5.18 0.64 to 76.91	5.17 0.54 to 84.91	5.04 0.58 to 82.70	5.18 0.52 to 98.85	4.77 0.06 to 291	4.78 0.31 to 119	4.39 0.60 to 65.22	4.28 0.55 to 61.83	4.17 0.36 to 82.55	4.22 0.15 to 126	3.53 0.14 to 108	3.49 0.39 to 56.05	2.98 0.06 to 129	3.01 0.27 to 56.82	2.91 0.38 to 43.99	2.87 0.19 to 60.07	2.86 0.18 to 74.32	2.67 0.22 to 50.79	2.62 0.31 to 40.10	2.26 0.24 to 39.69	2.12 0.26 to 34.07	1.45 0.03 to 72.66	DANU_PO

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.420 (95% CrI 0.246 to 0.651), log scale
Residual deviance: 153.9 for 160 data points
DIC: 268.6 (pD 114.7)
Largest R-hat: 1.010
Smallest ESS: bulk 1,166, tail 2,926
Divergent transitions: 0
Convergence: Not all met; read with caution
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Baseline HbA1c (percent) effect modifier, prognostic factor; 75 of 75	Background glucose lowering therapy (stratum S0 to S4) effect modifier, prognostic factor; 71 of 75
GETGOAL-L-ASIA S000488	8.53	S2
NCT00754988 S000027	7.96	S1
NCT02325960 S000058	8.18	S1
NCT01296412 S000080	8.15	S1
REWIND S000147	7.35	S4
STEP HFpEF DM S000161	6.8 median	S4
PB119 S000217	8.5	S0
NCT01001104 S000232	8.02	S0
PIONEER 10 S000234	8.31	S1
NCT02846233 S000236	9.99	S3
AWARD-7 S000237	8.6	S3
NCT00717457 S000414	8.1	S1
NCT00516074 S000435	7.31	S1
NCT00082407 S000441	8.6	S1
GETGOAL-S S000491	8.26	S1
NCT01175473 S000587	7.3	S1
NCT03829891 S000676	9.21	S1
PREVAIL S000693	6.57	S2
NCT00577824 S000752	8.22	S1
GetGoal-Duo1 S000792	7.6	S2
NCT01558271 S000837	8.14	S0
NCT00849017 S000852	8.07	S0
GRADE S000873	7.5	S1
GetGoal-O S000904	8.04	S4
NCT00135330 S000943	7.83	S1
NCT02200991 S001003	8.29	S2
NCT00097500 S001020	7.5	S1
AWARD-CHN1 S001064	7.97	S0
NCT01733758 S001075	8.11	S0
NCT05514535 S001161	7.9	S2
NCT03985293 S001191	8.08	S1
NCT00375492 S001222	7.62	not reported
NCT04504396 S001230	8.47	S1
NCT00360334 S001323	8.57	S1
NCT04552470 S001336	8.37	S0
SOLID-DKD S001370	7.61	S4
AWARD-CHN2 S001404	8.37	S1
NCT02324842 S001422	8.2	S1
GETGOAL-X S001439	7.96	S1
NCT00299871 S001455	7.55	S1
LIGHT-ON S001525	7.7	S1
NCT00460941 S001597	7.9	S1
NCT00744926 S001638	7.7	S0
SUSTAIN 8 S001847	8.25	S1
NCT02229227 S001887	7.7	S3
NCT00382239 S001906	7.98	S1
AGAC2 S001949	10.54	S3
NCT01632163 S001963	7.9	S2
NCT00676338 S001966	8.53	S0
NCT05086445 S001999	7.88	S0
NCT02887625 S002035	10	S1
AMPLITUDE-M S002081	8.07	S0
NCT02690883 S002088	9.05	S2
GETGOAL-M S002188	8.05	S1
NCT01455441 S002225	8.11	S1
NCT04466904 S002331	8.7	S4
GETGOAL-MONO S002333	8.03	S0
S002885 S002885	9.5	S1
S002946 S002946	6.45	S1
S002969 S002969	6.74 median	S1
S002991 S002991	10.3	S3
S002992 S002992	8.6	S2
S003023 S003023	7.05	S1
S003030 S003030	8.5	S1
S003047 S003047	8.35	S1
S003050 S003050	7.15	S1
S003071 S003071	7.8	S1
S003072 S003072	8	not reported
S003090 S003090	8.1	S3
S003094 S003094	8.74	S4
S003100 S003100	6.64	not reported
S003108 S003108	9.2	S0
S003426 S003426	7.8	S1
S003427 S003427	10.02	not reported
S003442 S003442	7.9	S0

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Baseline HbA1c: design means range from 6.5 (DULA_SC vs SEMA_SC) to 10.3 (INS_ASPART vs SEMA_SC) percent; threshold 0.5
FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 7.5 or less
NoteOutcome assessment, time point: selected time points span 0.43 to 386.13 weeks
NoteOutcome assessment, analysis set: mixed: completers 4, full_analysis 7, modified_itt 5, other 6, per_protocol 1, randomized 6, safety 46
NoteOutcome assessment, definition: mixed: adjudicated severe hypoglycemia while on assigned medication;measured glucose below 54 mg/dL in 30 days before any quarterly visit 1, adverse event term hypoglycemia, threshold not stated 1, all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period 1, any hypoglycemia, blood glucose below 70 mg/dL 1, Any hypoglycemia, including mild symptomatic 1, any hypoglycemic event, definition not given 1, any on therapy hypoglycemic event 1, Any signs or symptoms of hypoglycemia regardless of glucose 1, glucose below 60 mg/dL or symptoms relieved by glucose 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia adverse reaction, undefined 2, Hypoglycemia preferred term, mostly mild by investigator 1, hypoglycemia requiring third party assistance 1, hypoglycemia, definition not given 1, Hypoglycemia, not defined 1, incidence of hypoglycemia, definition not given 1, investigator reported symptomatic hypoglycemia 1, level 3 severe hypoglycemia 2, Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated 1, mild hypoglycemia, undefined 1, not stated 18, participants whose worst on therapy event had glucose below 3.1 mmol/L 1, participants with capillary glucose 3.0 mmol/L or lower 1, patient reported hypoglycemia events 1, Patients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuation 1, patients with any glucose below 70 mg/dL 1, severe (ADA) or blood glucose confirmed below 3.1 mmol/L with symptoms 1, severe hypoglycemia 2, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing third party assistance 1, Severe hypoglycemia requiring third party assistance 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe hypoglycemia, undefined 2, Severe hypoglycemia, undefined 1, severe symptomatic hypoglycemia 1, severe symptomatic hypoglycemia needing assistance 1, severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery 1, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery 1, severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery;symptomatic with glucose below 3.3 mmol/L or prompt recovery after treatment 1, severe, assistance of another person required 1, severe, requiring assistance of another person 2, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement 1, symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, symptomatic mild hypoglycemia, no glucose threshold printed 1, Symptoms or self monitored glucose below 3.4 mmol/L 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1, Zero implied by no hypoglycemia episodes of any kind 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 74, yes 1
NoteOutcome assessment, proportion method: mixed: not stated 72, observed 3
NoteOutcome assessment, intercurrent events (discontinuation): mixed: hypothetical 1, not stated 72, treatment_policy 1, while_on_treatment 1
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 1, not stated 72, treatment_policy 2
NoteRisk of bias, blinding: mixed: double_blind 35, not_reported 4, open_label 31, single_blind 5
NoteRisk of bias, funding: mixed: industry 53, mixed 5, non_industry 15, not_reported 2
NoteData handling, input conversions: arms_combined 24, count_from_percent 12, nonserious_only 7, printed_denominator 18

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	blinding	intercurrent events (rescue)	funding	start year	Eligibility
GETGOAL-L-ASIA	24	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT00754988	156	safety	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT02325960	16	safety	not stated	not stated	not stated	not stated	not stated	open_label	not stated	mixed	2015	age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
NCT01296412	26	safety	investigator reported symptomatic hypoglycemia	not stated	not stated	not stated	not stated	open_label	not stated	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
REWIND	365.26	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
STEP HFpEF DM	57	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2021	age 18 or older; heart failure with LVEF 45% or more; BMI 30 or more; type 2 diabetes with HbA1c 10% or less
PB119	24	safety	Severe hypoglycemia needing medical treatment	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	12	safety	all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	severe (ADA) or blood glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	while_on_treatment	single_blind	treatment_policy	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT02846233	16	randomized	any hypoglycemia, blood glucose below 70 mg/dL	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2016	age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin
AWARD-7	52	safety	Hypoglycaemia reported as treatment emergent adverse event	not stated	not stated	not stated	treatment_policy	single_blind	treatment_policy	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT00717457	104	safety	adverse event term hypoglycemia, threshold not stated	not stated	not stated	not stated	not stated	open_label	not stated	industry	2008	age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD
NCT00516074	12	modified_itt	severe hypoglycemia	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2007	age 18 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; metformin and/or thiazolidinedione
NCT00082407	52	modified_itt	Symptoms or self monitored glucose below 3.4 mmol/L	not stated	not stated	observed	not stated	open_label	not stated	industry	2003	Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40
GETGOAL-S	120	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
NCT01175473	4.43	safety	not stated	not stated	not stated	not stated	not stated	open_label	not stated	industry	2010	age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more
NCT03829891	16	full_analysis	patient reported hypoglycemia events	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2018	age 18 to 70; diabetes 6 months or more on stable oral agents; HbA1c 7.5 to 11.0 percent; BMI 21 to 35
PREVAIL	20	modified_itt	participants with capillary glucose 3.0 mmol/L or lower	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2014	age 30 to 80; T2D 7 years or less; A1c 6.0 to 9.5 percent off drugs or 5.5 to 9.0 on up to 2 oral drugs
NCT00577824	24	full_analysis	Any signs or symptoms of hypoglycemia regardless of glucose	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
GetGoal-Duo1	24.43	safety	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery;symptomatic with glucose below 3.3 mmol/L or prompt recovery after treatment	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271	52	safety	severe, assistance of another person required	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	164	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
GRADE	386.13	per_protocol	adjudicated severe hypoglycemia while on assigned medication;measured glucose below 54 mg/dL in 30 days before any quarterly visit	not stated	yes	not stated	hypothetical	single_blind	hypothetical	mixed	2013	age at diagnosis 30 or older; T2D under 10 years; HbA1c 6.8 to 8.5 percent; metformin 1000 mg/day or more
GetGoal-O	24.43	safety	severe symptomatic hypoglycemia	not stated	not stated	observed	not stated	double_blind	not stated	industry	2013	age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher
NCT00135330	20	full_analysis	incidence of hypoglycemia, definition not given	not stated	not stated	not stated	not stated	open_label	not stated	industry	2005	age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	open_label	not stated	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
NCT00097500	64	other	Severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	open_label	not stated	industry	2004	age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
NCT01733758	52	safety	any on therapy hypoglycemic event	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2013	Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	open_label	not stated	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
NCT03985293	20	safety	TEAE preferred term hypoglycemia, not necessarily protocol defined	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT00375492	24	randomized	any hypoglycemic event, definition not given	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2006	type 2 diabetes; weight loss trial
NCT04504396	24	safety	severe hypoglycemia with severe cognitive impairment needing medical treatment	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2020	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg
NCT00360334	26	full_analysis	severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	open_label	not stated	industry	2006	BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
NCT04552470	12	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2020	Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
AWARD-CHN2	52	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	open_label	not stated	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 11.0 percent on metformin and/or sulfonylurea
NCT02324842	17.38	safety	not stated	not stated	not stated	not stated	not stated	open_label	not stated	industry	2014	T2DM, HbA1c 7 to 11 percent, eGFR 60 or more, drug naive or metformin with or without SU
GETGOAL-X	116	safety	severe symptomatic needing assistance with glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	open_label	not stated	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT00299871	13.43	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2006	age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
LIGHT-ON	26	safety	not stated	not stated	not stated	not stated	not stated	open_label	not stated	mixed	2014	age 30 to 75, HbA1c 6.5 to 10 percent on metformin, NAFLD with MRI-PDFF over 10 percent, BMI 20 to 35
NCT00460941	12	safety	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2007	age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
NCT00744926	24	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
SUSTAIN 8	57	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2017	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated
NCT02229227	26	safety	participants whose worst on therapy event had glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	open_label	not stated	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
NCT00382239	12	full_analysis	Hypoglycemia preferred term, mostly mild by investigator	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2006	age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
AGAC2	0.43	randomized	severe hypoglycemia	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2011	age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
NCT00676338	26	full_analysis	Major: loss of consciousness or seizure, or glucose below 3.0 mmol/L needing assistance;Minor confirmed: symptoms with glucose below 3.0 mmol/L, self treated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
NCT02887625	78.21	other	glucose below 60 mg/dL or symptoms relieved by glucose	not stated	not stated	observed	not stated	open_label	not stated	mixed	2015	age 18 to 75; HbA1c above 7.5 percent on near maximal metformin plus sulfonylurea
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
NCT02690883	24	safety	Patients declaring any hypoglycemia, definition not printed;Severe hypoglycemia, undefined, leading to discontinuation	not stated	not stated	not stated	not stated	open_label	not stated	industry	2016	age 18 or older; eGFR 30 or more; UAER above 0.3 g/24 h
GETGOAL-M	76.43	safety	severe symptomatic hypoglycemia needing assistance of another person, glucose below 2.0 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT01455441	16	completers	Zero implied by no hypoglycemia episodes of any kind	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2011	age over 18; HbA1c 7 to 11 percent; BMI over 25; diet or metformin; sedentary
NCT04466904	20	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2020	age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
GETGOAL-MONO	12.43	safety	symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2008	age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
S002885	12	other	symptomatic mild hypoglycemia, no glucose threshold printed	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2019	age 20 to 75; HbA1c 7.0 or more on metformin and glimepiride; eGFR 30 or more
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	open_label	not stated	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S002969	52.14	safety	not stated	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2018	age 18 to 70; BMI 30 to 50; HbA1c 48 to below 97 mmol/mol; T2DM under 10 years; undergoing LAGB
S002991	13.04	other	hypoglycemia adverse reaction, undefined	not stated	not stated	not stated	not stated	not_reported	not stated	non_industry	2023	age 65 or older; newly diagnosed T2D; UACR 30 to 300 mg/g; eGFR 60 to 90
S002992	26	safety	not stated	not stated	not stated	not stated	not stated	open_label	not stated	industry		adults 18 or older; HbA1c 7.5 to 10 percent; BMI 20 to less than 40; basal insulin 20 to 50 U plus metformin with or without SGLT2i
S003023	0.43	modified_itt	not stated	not stated	not stated	not stated	not stated	single_blind	not stated	non_industry		age 20 to 80, T2D not on insulin, elective CABG or valve surgery with cardiopulmonary bypass
S003030	52	full_analysis	severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	open_label	not stated	industry	2015	age 20 to 75; HbA1c 7.5 to 11 percent; two or more oral agents for 3 months
S003047	6.57	safety	Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement	not stated	not stated	not stated	not stated	double_blind	not stated	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003050	12	safety	not stated	not stated	not stated	not stated	not stated	not_reported	not stated	non_industry	2020	age 18 to 65; diabetes 2 years or less, no ASCVD; HbA1c 7.0 to 7.5 percent; BMI 18.5 to 30; metformin 1000 mg
S003071	24	randomized	hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2010	age 18 to under 80; HbA1c 6.9 to 9.4 percent NGSP; BMI 35 or less; on sulfonylurea
S003072	14	completers	not stated	not stated	not stated	not stated	not stated	open_label	not stated	mixed	2011	age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more
S003090	1	modified_itt	patients with any glucose below 70 mg/dL	not stated	not stated	not stated	not stated	open_label	not stated	not_reported		age over 18; type 2 diabetes over 3 months; noncritical inpatients; prior insulin under 10 units/day
S003094	12	completers	Severe hypoglycemia requiring third party assistance	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2011	HbA1c 7.5 to 11%; BMI 25 or more; waist 90 cm men, 85 cm women; insulin 10 U/day or more for 3 months
S003100	13.04	completers	hypoglycemia, definition not given	not stated	not stated	not stated	not stated	open_label	not stated	non_industry	2019	age 18 to 75; T2D; OSA with AHI above 15 on CPAP; no DPP4i or GLP-1 RA
S003108	24	randomized	Any hypoglycemia, including mild symptomatic	not stated	not stated	not stated	not stated	single_blind	not stated	non_industry	2012	T2D with coronary artery disease; no severe heart failure; creatinine up to 150 umol/L
S003426	24	safety	mild hypoglycemia, undefined	not stated	not stated	not stated	not stated	open_label	not stated	non_industry		adults with type 2 diabetes; HbA1c 6.5 to 8.0 percent; BMI 30 to 35; stable metformin and empagliflozin
S003427	52.14	other	hypoglycemia adverse reaction, undefined	not stated	not stated	not stated	not stated	not_reported	not stated	non_industry	2019	adults with type 2 diabetes, stable treatment, measurable CIMT; no prior CVD events
S003442	24	other	Hypoglycemia, not defined	not stated	not stated	not stated	not stated	not_reported	not stated	non_industry	2019	Women with T2D by ADA criteria; no weight loss drugs within 24 weeks

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT00754988	A2+A3	TASP_SC	156	arm, events	36 / 388	arms_combined	R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	18 / 185		R0022521:Table 2
NCT02325960	A1	EXEN_SC	16	arm, events	0 / 22		R0024438:Results
NCT02325960	A2	INS_GLARGINE	16	arm, events	0 / 23		R0024438:Results
NCT01296412	A1	SITAGLIPTIN	26	arm, events	39 / 326		R0026295:Table 3
NCT01296412	A2	LIRA_SC	26	arm, events	13 / 327		R0026295:Table 3
REWIND	A1	PLACEBO	365.26	arm, events	354 / 4,952	nonserious_only	registry:adverse_events
REWIND	A2	DULA_SC	365.26	arm, events	413 / 4,949	nonserious_only	registry:adverse_events
STEP HFpEF DM	A1	SEMA_SC	57	arm, events	30 / 310		R0018972:Table 4
STEP HFpEF DM	A2	PLACEBO	57	arm, events	21 / 306		R0018972:Table 4
PB119	A1	VISEPE_SC	24	arm, events	6 / 137		R0011471:Table 4
PB119	A2	PLACEBO	24	arm, events	1 / 136		R0011471:Table 4
NCT01001104	A1	PLACEBO	12	arm, events	0 / 37		R0015000:Table 3
NCT01001104	A2+A3+A4	DULA_SC	12	arm, events	3 / 108	arms_combined	R0015000:Table 3
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	67 / 393	arms_combined	R0018421:Table 3
PIONEER 10	A4	DULA_SC	57	arm, events	13 / 65		R0018421:Table 3
NCT02846233	A1	DULA_SC	16	arm, events	0 / 12		R0028441:Table 5
NCT02846233	A2	OTHER_ACTIVE_basal_bolus_insulin	16	arm, events	1 / 10		R0028441:Table 5
AWARD-7	A1	INS_GLARGINE	52	arm, events	16 / 194		R0017387:Table 2
AWARD-7	A2+A3	DULA_SC	52	arm, events	12 / 383	arms_combined	R0017387:Table 2
NCT00717457	A1+A2	TASP_SC	104	arm, events	119 / 797	arms_combined	R0013639:Table 2
NCT00717457	A3	EXEN_SC	104	arm, events	79 / 392		R0013639:Table 2
NCT00516074	A1	EXEN_SC	12	arm, events	2 / 28	count_from_percent	R0019195:Results
NCT00516074	A2	PLACEBO	12	arm, events	1 / 26	count_from_percent	R0019195:Results
NCT00082407	A1	EXEN_SC	52	arm, events	134 / 255	count_from_percent	registry:outcomes
NCT00082407	A2	INS_PREMIX	52	arm, events	128 / 250	count_from_percent	registry:outcomes
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	66 / 154		R0022626:Table 2
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	37 / 157		R0022626:Table 2
GETGOAL-S	A1	PLACEBO	120	arm, events	51 / 286		registry:outcomes
GETGOAL-S	A2	LIXI_SC	120	arm, events	127 / 573		registry:outcomes
NCT01175473	A1	LIXI_SC	4.43	arm, events	0 / 77		R0022723:Table 3
NCT01175473	A2	LIRA_SC	4.43	arm, events	0 / 71		R0022723:Table 3
NCT03829891	A1	BEIN_SC	16	arm, events	5 / 35		R0007581:Results
NCT03829891	A2	INS_GLARGINE	16	arm, events	9 / 33		R0007581:Results
PREVAIL	A1	STANDARD_CARE	20	arm, events	15 / 33		R0010144:Table 3
PREVAIL	A2	INS_LISPRO	20	arm, events	12 / 35		R0010144:Table 3
PREVAIL	A3	EXEN_SC	20	arm, events	6 / 35		R0010144:Table 3
NCT00577824	A1	PLACEBO	24	arm, events	8 / 36		R0018881:Table 2
NCT00577824	A2+A3	EXEN_SC	24	arm, events	79 / 145	arms_combined	R0018881:Table 2
GetGoal-Duo1	A1	PLACEBO	24.43	arm, events	30 / 223		registry:outcomes
GetGoal-Duo1	A2	LIXI_SC	24.43	arm, events	50 / 223		registry:outcomes
NCT01558271	A1	DULA_SC	52	arm, events	8 / 281		R0011754:Results
NCT01558271	A2	LIRA_SC	52	arm, events	4 / 141		R0011754:Results
NCT00849017	A1	PLACEBO	164	arm, events	8 / 105	nonserious_only	registry:adverse_events
NCT00849017	A2+A3	ALBI_SC	164	arm, events	15 / 204	nonserious_only;arms_combined	registry:adverse_events
GRADE	A1	INS_GLARGINE	386.13	arm, events	659 / 1,263		R0020895:Table 2
GRADE	A2	GLIMEPIRIDE	386.13	arm, events	833 / 1,254		R0020895:Table 2
GRADE	A3	LIRA_SC	386.13	arm, events	375 / 1,262		R0020895:Table 2
GRADE	A4	SITAGLIPTIN	386.13	arm, events	361 / 1,268		R0020895:Table 2
GetGoal-O	A1	LIXI_SC	24.43	arm, events	13 / 176	count_from_percent	registry:outcomes
GetGoal-O	A2	PLACEBO	24.43	arm, events	10 / 174	count_from_percent	registry:outcomes
NCT00135330	A1	EXEN_SC	20	arm, events	8 / 45		registry:outcomes
NCT00135330	A2	EXENROSI_SC	20	arm, events	9 / 47		registry:outcomes
NCT00135330	A3	ROSIGLITAZONE	20	arm, events	6 / 45		registry:outcomes
NCT02200991	A1	LIXI_SC	4.43	arm, events	11 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	1 / 67		R0024589:Table 3
NCT00097500	A1	EXEN_SC	64	arm, events	3 / 36	count_from_percent	R0027264:Results
NCT00097500	A2	INS_GLARGINE	64	arm, events	8 / 33	count_from_percent	R0027264:Results
AWARD-CHN1	A1+A2	DULA_SC	26	arm, events	23 / 492	arms_combined	R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	38 / 245		R0014229:Table 2
NCT01733758	A2+A3	ALBI_SC	52	arm, events	14 / 310	printed_denominator;arms_combined	R0010997:Results
NCT01733758	A4	LIRA_SC	52	arm, events	3 / 103	printed_denominator	R0010997:Results
NCT05514535	A1	SEMA_SC	45	arm, events	14 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	21 / 285		R0015842:Table 2
NCT03985293	A1	PLACEBO	20	arm, events	0 / 66		R0006095:Table 3
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	15 / 346	arms_combined	R0006095:Table 3
NCT00375492	A1	EXEN_SC	24	arm, events	33 / 96		registry:outcomes
NCT00375492	A2	PLACEBO	24	arm, events	30 / 98		registry:outcomes
NCT04504396	A1	VISEPE_SC	24	arm, events	8 / 310		R0009432:Table 3
NCT04504396	A2	PLACEBO	24	arm, events	10 / 310		R0009432:Table 3
NCT00360334	A1	EXEN_SC	26	arm, events	37 / 118		R0024925:Table 3
NCT00360334	A2	INS_GLARGINE	26	arm, events	68 / 117		R0024925:Table 3
NCT04552470	A1	PLACEBO	12	arm, events	0 / 9		R0004540:Results
NCT04552470	A2+A3+A4	DANU_PO	12	arm, events	1 / 28	arms_combined	R0004540:Results
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	10 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	2 / 94		R0004355:Table 2
AWARD-CHN2	A1+A2	DULA_SC	52	arm, events	109 / 515	arms_combined	R0023722:Table 2
AWARD-CHN2	A3	INS_GLARGINE	52	arm, events	88 / 259		R0023722:Table 2
NCT02324842	A1	CANAGLIFLOZIN	17.38	arm, events	0 / 15	nonserious_only	registry:adverse_events
NCT02324842	A2	LIRA_SC	17.38	arm, events	3 / 15	nonserious_only	registry:adverse_events
NCT02324842	A3	CANALIRA_SC	17.38	arm, events	3 / 15	nonserious_only	registry:adverse_events
GETGOAL-X	A1	LIXI_SC	116	arm, events	16 / 320		registry:outcomes
GETGOAL-X	A2	EXEN_SC	116	arm, events	46 / 319		registry:outcomes
NCT00299871	A1	PLACEBO	13.43	arm, events	1 / 109		R0021613:Table 3
NCT00299871	A2+A3+A4+A5+A6+A7+A8+A9	LIXI_SC	13.43	arm, events	13 / 433	arms_combined	R0021613:Table 3
LIGHT-ON	A1	LIRA_SC	26	arm, events	0 / 24		R0024860:Table 5
LIGHT-ON	A2	SITAGLIPTIN	26	arm, events	1 / 27		R0024860:Table 5
LIGHT-ON	A3	INS_GLARGINE	26	arm, events	2 / 24		R0024860:Table 5
NCT00460941	A1	PLACEBO	12	arm, events	1 / 32	printed_denominator	R0021258:Results
NCT00460941	A2+A3+A4	TASP_SC	12	arm, events	6 / 97	printed_denominator;arms_combined	R0021258:Results
NCT00744926	A1	PLACEBO	24	arm, events	1 / 123	printed_denominator	R0025346:Table 1
NCT00744926	A2+A3	TASP_SC	24	arm, events	11 / 245	printed_denominator;arms_combined	R0025346:Table 1
SUSTAIN 8	A1	SEMA_SC	57	arm, events	6 / 394		registry:outcomes
SUSTAIN 8	A2	CANAGLIFLOZIN	57	arm, events	5 / 394		registry:outcomes
NCT02229227	A1	ALBI_SC	26	arm, events	230 / 402		R0008089:Table 3
NCT02229227	A2	INS_LISPRO	26	arm, events	309 / 412		R0008089:Table 3
NCT00382239	A1	PLACEBO	12	arm, events	4 / 40		R0027621:Table 3
NCT00382239	A2+A3+A4	EXEN_SC	12	arm, events	46 / 113	arms_combined	R0027621:Table 3
AGAC2	A1	PLACEBO	0.43	arm, events	9 / 21		R0020827:Supplementary Table 2
AGAC2	A2	EXEN_SC	0.43	arm, events	12 / 30		R0020827:Supplementary Table 2
NCT01632163	A1	LIXI_SC	24	arm, events	35 / 224		R0014725:Results
NCT01632163	A2	PLACEBO	24	arm, events	30 / 224		R0014725:Results
NCT00676338	A1	EXENER_SC	26	arm, events	13 / 248		R0027761:Results
NCT00676338	A2	METFORMIN	26	arm, events	10 / 246		R0027761:Results
NCT00676338	A3	PIOGLITAZONE	26	arm, events	6 / 163		R0027761:Results
NCT00676338	A4	SITAGLIPTIN	26	arm, events	5 / 163		R0027761:Results
NCT05086445	A1	PLACEBO	14	arm, events	0 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	1 / 49	arms_combined	R0003844:Table 2
NCT02887625	A1	EXENER_SC	78.21	arm, events	81 / 129	count_from_percent	R0026120:Results
NCT02887625	A2	OTHER_ACTIVE_basal_bolus_insulin	78.21	arm, events	98 / 122	count_from_percent	R0026120:Results
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	2 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	0 / 102		R0007136:Table 2
NCT02690883	A1	INS_LISPRO	24	arm, events	20 / 46		R0011086:Results
NCT02690883	A2	EXEN_SC	24	arm, events	10 / 46		R0011086:Results
GETGOAL-M	A1+A2	LIXI_SC	76.43	arm, events	40 / 510	arms_combined	registry:outcomes
GETGOAL-M	A3	PLACEBO	76.43	arm, events	4 / 170	printed_denominator	registry:outcomes
NCT01455441	A1	LIRA_SC	16	arm, events	0 / 18		R0010221:Results
NCT01455441	A2	PLACEBO	16	arm, events	0 / 16		R0010221:Results
NCT04466904	A1+A2+A3	MAZD_SC	20	arm, events	2 / 24	arms_combined	R0009340:Table 2
NCT04466904	A4	DULA_SC	20	arm, events	0 / 6	printed_denominator	R0009340:Table 2
NCT04466904	A5	PLACEBO	20	arm, events	0 / 12	printed_denominator	R0009340:Table 2
GETGOAL-MONO	A1	PLACEBO	12.43	arm, events	2 / 122	printed_denominator	R0022843:Table 2
GETGOAL-MONO	A2+A3	LIXI_SC	12.43	arm, events	4 / 239	arms_combined	R0022843:Table 2
S002885	A1	DULA_SC	12	arm, events	1 / 13		R0003420:Results
S002885	A2	EMPAGLIFLOZIN	12	arm, events	2 / 12		R0003420:Results
S002946	A1	SEMA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002969	A1	LIRA_SC	52.14	arm, events	0 / 13		R0010852:Supplementary Clinical Sequelae 1
S002969	A2	PLACEBO	52.14	arm, events	1 / 14		R0010852:Supplementary Clinical Sequelae 1
S002991	A1	SEMA_SC	13.04	arm, events	2 / 110		R0009861:Results
S002991	A2	INS_ASPART	13.04	arm, events	5 / 110		R0009861:Results
S002992	A1	IGLARLIXI_SC	26	arm, events	114 / 443		R0019745:Figure 1
S002992	A2	INS_PREMIX	26	arm, events	170 / 444		R0019745:Figure 1
S003023	A1	LIRA_SC	0.43	arm, events	0 / 32	printed_denominator	R0017408:Results
S003023	A2	STANDARD_CARE	0.43	arm, events	0 / 28	printed_denominator	R0017408:Results
S003030	A1	EXEN_SC	52	arm, events	1 / 33		R0018574:Results
S003030	A2	INS_PREMIX	52	arm, events	5 / 33		R0018574:Results
S003047	A1+A2	LIXI_SC	6.57	arm, events	17 / 80	printed_denominator;arms_combined	R0016337:Table 3
S003047	A3	PLACEBO	6.57	arm, events	3 / 40	printed_denominator	R0016337:Table 3
S003050	A1	METFORMIN	12	arm, events	0 / 30		R0021314:Results
S003050	A2	DULA_SC	12	arm, events	0 / 30		R0021314:Results
S003071	A1	LIRA_SC	24	arm, events	9 / 50		R0023696:Results
S003071	A2	SITAGLIPTIN	24	arm, events	5 / 49		R0023696:Results
S003072	A1	VILDAGLIPTIN	14	arm, events	0 / 62		R0023470:Results
S003072	A2	LIRA_SC	14	arm, events	0 / 60		R0023470:Results
S003090	A1	STANDARD_CARE	1	arm, events	1 / 27	printed_denominator	R0025350:Table 3
S003090	A2	DULA_SC	1	arm, events	0 / 27	printed_denominator	R0025350:Table 3
S003094	A1	LIRA_SC	12	arm, events	5 / 42	count_from_percent	R0026794:Results
S003094	A2	OTHER_ACTIVE_insulin_dose_increase	12	arm, events	13 / 42	count_from_percent	R0026794:Results
S003100	A1	LIRA_SC	13.04	arm, events	2 / 45		R0021058:Table 5
S003100	A2	STANDARD_CARE	13.04	arm, events	1 / 45		R0021058:Table 5
S003108	A1+A3	LIRA_SC	24	arm, events	5 / 60	arms_combined	R0025278:Table 4
S003108	A2	METFORMIN	24	arm, events	1 / 30		R0025278:Table 4
S003108	A4	LIRAMETF_SC	24	arm, events	3 / 30		R0025278:Table 4
S003426	A1	SEMA_SC	24	arm, events	1 / 38		R0040396:Table 3
S003426	A2	TIRZ_SC	24	arm, events	2 / 41		R0040396:Table 3
S003427	A1	LIRA_SC	52.14	arm, events	3 / 74		R0044046:Table IV
S003427	A2	SEMA_SC	52.14	arm, events	3 / 74		R0044046:Table IV
S003442	A1	DULA_SC	24	arm, events	1 / 48	printed_denominator	R0016372:Table 4
S003442	A2	LIRA_SC	24	arm, events	2 / 48	printed_denominator	R0016372:Table 4

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab